Navigation Links
Champions Oncology Reports Financial Results for the Year Ended April 30, 2012
Date:7/18/2012

HACKENSACK, N.J., July 18, 2012 /PRNewswire/ -- Champions Oncology, Inc. (OTC: CSBR), formerly Champions Biotechnology, Inc., engages in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, announced today its financial results for the year ended April 30, 2012.

Joel Ackerman, the CEO of Champions Oncology, stated, "Fiscal 2012 was a year of great progress for the company.  We demonstrated our ability to drive significant volume growth in both sides of our business.  We continue to evolve our strategic direction to better align the strength of our technology platform with the needs of the market.  Within this new approach, we made significant progress in expanding our customer base and building a solid operational foundation for the future."

Operating revenues were $7.1 million and $6.9 million for the years ended April 30, 2012 and 2011, respectively.

Total operating expenses were $16.2 million and $12.1 million for the years ended April 30, 2012 and 2011, respectively.

Champions reported a net loss of $8.7 million, or ($0.19) per share and $3.8 million, or ($0.11) per share for the years ended April 30, 2012 and 2011, respectively.

Excluding stock based compensation of $3.3 million, Champions recognized a net loss of $5.3* million, or ($0.11*) per share, and excluding stock based compensation of $3.1 million, a net loss of $0.7* million, or ($0.02*), per share for the years ended April 30, 2012 and 2011, respectively.

During fiscal 2012, we modified our POS business strategy to focus on growing our core technology products, which includes TumorGraft implants and drug studies.  As part of this strategy, we significantly reduced the price of our core technology products to make the products affordable to a broader patient base and to accelerate the growth of our Tumorbank.  In addition, we have increased spending on sales an
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities
2. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
3. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
4. OvaGene Oncology Collaborates With Moffitt Cancer Center to Develop and Commercialize microRNAs Associated With Chemotherapeutic Drug Response
5. US Oncology Research Affiliated Physician to Present Findings From Innovative Clinical Trial at 2011 CTRC-AACR San Antonio Breast Cancer Symposium
6. Peer-reviewed Article Reports ProImmune's Immune Formulation 200® Activates the Immune-Support Gene Nrf2.
7. Prosperous Agriculture Reports Outstanding Sales Result for First Half of 2012
8. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2012
9. GeneLink Reports First Quarter 2012 Financial Results
10. Genesis Biopharma Mentioned Favorably in BioMedReports Article
11. Vermillion Reports First Quarter 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 29, 2014 Transparency Market Research, in ... SPPS, LPPS, HPPS, by Application - Cancer, Metabolic, CVS, ... and by Delivery) - Global Industry Analysis, Size, Share, ... the global peptide therapeutics market was worth US$14.1 billion ... by 2018 at an 8.7% CAGR. , The two ...
(Date:9/29/2014)... , Sept. 29, 2014 Burnham Securities ... Channel Group ("TCG"), a leader in healthcare venture ... formed an alliance to expand the range of ... With the alliance, Burnham Securities will be supported ... clinical medicine and management in healthcare industry to ...
(Date:9/29/2014)... 2014 Latest study ... transform network connectivity as customers put quality and ... ProLabs , the leading independent provider of global ... of their survey conducted at the 2014 European ... communications professionals from across the globe. ...
(Date:9/29/2014)... 29, 2014  Perrigo Company plc (NYSE: ... has transferred a portfolio of preclinical research assets, ... of Elan Corporation plc, to drug discovery and ... agreement, Perrigo will receive an upfront payment in ... on any future sales derived from the portfolio. ...
Breaking Biology Technology:Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3End of an Era: OEM Dominance - Could it be a Thing of the Past? 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 2Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 3Perrigo Announces the Out-Licensing of Preclinical Assets to Imago Pharmaceuticals 4
... 29 Tutogen Medical, Inc.,(Amex: TTG ), a ... (allograft) and animal (xenograft) tissue, announced today,that Guy L. ... the Roth Capital Partners New York Investor Conference on,Thursday, ... conference is,being held at The Westin NY at Times ...
... N.Y., Aug. 29 Emisphere,Technologies, Inc. (Nasdaq: ... been appointed to the position of Chief Financial ... CFO and Interim Chief Executive Officer,of Astralis, Ltd., ... Michael V. Novinski, President and Chief Executive Officer. ...
... PHRM ) today announced that the U.S. ... designation for oral Azacitidine in the,treatment of Myelodysplastic ... to facilitate the development and,expedite the review of ... or,life-threatening conditions and that demonstrate the potential to ...
Cached Biology Technology:Tutogen Medical, Inc. to Present at the Roth Capital Partners 2007 New York Conference 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 2Emisphere Technologies, Inc. Appoints Michael R. Garone chief financial officer 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 2Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 3Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 4Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 5Pharmion's Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes 6
(Date:9/29/2014)... article published online in Behavioral Brain Research ... brain as a result of chronic alcohol exposure that ... , Clinical assessments and research indicate that individuals with ... This can occur when people are actively drinking, when ... abstaining. , "Sleep-wake disturbances can last for months, ...
(Date:9/29/2014)... when the supercontinent of Pangea was starting to break up ... kinds of reptiles called phytosaurs and rauisuchids were at the ... the two top predators didn,t interact much as the former ... land. But those ideas are changing, thanks largely to the ... online in September in the German journal Naturwissenschaften ...
(Date:9/29/2014)... Growing Demand From Huge ... Security Concerns Continue to Propel Biometrics Market in ... is one of the fastest growing biometrics markets ... majorly in various government projects such as National ... biometrics dominates the country,s biometrics market, with other ...
Breaking Biology News(10 mins):Tooth buried in bone shows prehistoric predators tangled across land, sea 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 2India Biometrics Market to Surpass USD2.7 Billion by 2019, Finds TechSci Research Study 3
... flat. Even the flattest of basement membranes has topography; ... , Unlike the princess kept awake by the ... cultured on a substrate deliberately printed with nanoscale ... of Wisconsin–Madison. , The researchers used soft ...
... been stopped early due to preliminary results indicating that ... HIV during heterosexual intercourse by 53 percent. , The ... 12 to review the interim data. Based on the ... trial and recommended that all men enrolled in the ...
... Give or take a few dozen trillions, a human adult ... roundworm has exactly 959 cells. , Yet we have ... University, who has been exploring two “highly conserved? cell-signaling pathways ... we have a lot of common enemies, particularly soil-borne ...
Cached Biology News:Embryonic stem cells do better on bumpy nanoscale mattress 2Male circumcision reduces HIV risk, study stopped early 2Male circumcision reduces HIV risk, study stopped early 3Worms produce surprise insight into human fever 2
...
... The new IKATUBE ULTRA TURRAX Tube Disperser System ... homogenizing system. It offers a cleaner, safer, and ... system processes sample volumes from 2 to 15 ... type, researchers can choose one of 4 different ...
...
... Triple-angle light scattering detector for ... digital signal processing hardware for two ... UV detectors. Also contains an analog ... interfacing to strip chart recorders. Includes ...
Biology Products: